Robin Kral

Corporate Officer/Principal en REATA PHARMACEUTICALS, INC. .

Consumer Services

Health Technology

Perfil

Robin Kral currently works at Reata Pharmaceuticals, Inc., as Vice President-Licensing & Intellectual Property from 2004.
Mr. Kral also formerly worked at The University of Texas Southwestern Medical Center, as Associate Director-Venture Development and NPS Pharmaceuticals, Inc., as Principal.
Mr. Kral received his undergraduate degree and graduate degree from Texas Tech University and Masters Business Admin degree from David Eccles School of Business.

Cargos activos de Robin Kral

Empresas	Cargo	Inicio
REATA PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/01/2004

Todos los cargos activos de Robin Kral

Antiguos cargos conocidos de Robin Kral.

Empresas	Cargo	Fin
The University of Texas Southwestern Medical Center	Corporate Officer/Principal	-
NPS PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Robin Kral.

Formación de Robin Kral.

Texas Tech University	Graduate Degree
David Eccles School of Business	Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Robin Kral.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
NPS Pharmaceuticals, Inc. NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ.	Health Technology
Reata Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.	Health Technology